First Detection of blaIMP-1 in clinical isolated multiresistant acinetobacter baumannii from Korea

Seok Hoon Jeong, Il Kwon Bae, Seung Ghyu Sohn, Kwang Ok Park, Young Jun An, Kwang Hoon Sung, Seon Ju Jang, Myong Jin Heo, Ki Suk Yang, Sang Hee Lee

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Among 46 Acinetobacter baumannii isolates collected in 2004, two imipenem-resistant isolates were obtained from clinical specimens taken from patients hospitalized in Busan, Republic of Korea. Two carbapenemase-producing isolates were further investigated to determine the mechanism of resistance. These isolates were analyzed by antibiotic susceptibility testing, microbiological tests of carbapenemase activity, determination of pI, transconjugation test, enterobacterial repetitive consensus (ERIC)-PCR, and DNA sequencing. Two cases of infection by A. baumannii producing the IMP-1 β-lactamase were detected. The isolates were characterized by a modified cloverleaf synergy test and EDTA-disk synergy test. Isoelectric focusing of crude bacterial extracts revealed nitrocefin-positive bands with a pI value of 9.0. PCR amplification and characterization of the amplicons by direct sequencing indicated that the isolates carried a blaIMP-1 determinant. The isolates were characterized by a multidrug resistance phenotype, including penicillins, extended-spectrum cephalosporins, carbapenems, and aminoglycosides. These results indicate that the observed imipenem resistance of two Korean A. baumannii isolates was due to the spread of an IMP-1-producing clone. Our microbiological test of carbapenemase activity is simple to screen class B metallo-β-lactamase-producing clinical isolates to determine their clinical impact and to prevent further spread. This study shows that the blaIMP-1 resistance determinant, which is emerging in Korea, may become an emerging therapeutic problem, since clinicians are advised not to use extended-spectrum cephalosporins, imipenem, and aminoglycosides. This observation emphasizes the importance of having effective control measures in Asian hospitals, such as early detection of colonized patients, isolation procedures, and a judicious use of antibiotics.

Original languageEnglish
Pages (from-to)1377-1383
Number of pages7
JournalJournal of microbiology and biotechnology
Volume16
Issue number9
Publication statusPublished - 2006 Sep 1

Fingerprint

Acinetobacter baumannii
Imipenem
Korea
Inosine Monophosphate
Aminoglycosides
Cephalosporins
Patient Isolation
Anti-Bacterial Agents
Polymerase Chain Reaction
Republic of Korea
Carbapenems
Isoelectric Focusing
Multiple Drug Resistance
Complex Mixtures
DNA Sequence Analysis
Edetic Acid
Penicillins
Clone Cells
Phenotype
Infection

All Science Journal Classification (ASJC) codes

  • Biotechnology
  • Applied Microbiology and Biotechnology

Cite this

Jeong, S. H., Bae, I. K., Sohn, S. G., Park, K. O., An, Y. J., Sung, K. H., ... Lee, S. H. (2006). First Detection of blaIMP-1 in clinical isolated multiresistant acinetobacter baumannii from Korea. Journal of microbiology and biotechnology, 16(9), 1377-1383.
Jeong, Seok Hoon ; Bae, Il Kwon ; Sohn, Seung Ghyu ; Park, Kwang Ok ; An, Young Jun ; Sung, Kwang Hoon ; Jang, Seon Ju ; Heo, Myong Jin ; Yang, Ki Suk ; Lee, Sang Hee. / First Detection of blaIMP-1 in clinical isolated multiresistant acinetobacter baumannii from Korea. In: Journal of microbiology and biotechnology. 2006 ; Vol. 16, No. 9. pp. 1377-1383.
@article{7018cd6aa41d40359ca290e78d5b8dab,
title = "First Detection of blaIMP-1 in clinical isolated multiresistant acinetobacter baumannii from Korea",
abstract = "Among 46 Acinetobacter baumannii isolates collected in 2004, two imipenem-resistant isolates were obtained from clinical specimens taken from patients hospitalized in Busan, Republic of Korea. Two carbapenemase-producing isolates were further investigated to determine the mechanism of resistance. These isolates were analyzed by antibiotic susceptibility testing, microbiological tests of carbapenemase activity, determination of pI, transconjugation test, enterobacterial repetitive consensus (ERIC)-PCR, and DNA sequencing. Two cases of infection by A. baumannii producing the IMP-1 β-lactamase were detected. The isolates were characterized by a modified cloverleaf synergy test and EDTA-disk synergy test. Isoelectric focusing of crude bacterial extracts revealed nitrocefin-positive bands with a pI value of 9.0. PCR amplification and characterization of the amplicons by direct sequencing indicated that the isolates carried a blaIMP-1 determinant. The isolates were characterized by a multidrug resistance phenotype, including penicillins, extended-spectrum cephalosporins, carbapenems, and aminoglycosides. These results indicate that the observed imipenem resistance of two Korean A. baumannii isolates was due to the spread of an IMP-1-producing clone. Our microbiological test of carbapenemase activity is simple to screen class B metallo-β-lactamase-producing clinical isolates to determine their clinical impact and to prevent further spread. This study shows that the blaIMP-1 resistance determinant, which is emerging in Korea, may become an emerging therapeutic problem, since clinicians are advised not to use extended-spectrum cephalosporins, imipenem, and aminoglycosides. This observation emphasizes the importance of having effective control measures in Asian hospitals, such as early detection of colonized patients, isolation procedures, and a judicious use of antibiotics.",
author = "Jeong, {Seok Hoon} and Bae, {Il Kwon} and Sohn, {Seung Ghyu} and Park, {Kwang Ok} and An, {Young Jun} and Sung, {Kwang Hoon} and Jang, {Seon Ju} and Heo, {Myong Jin} and Yang, {Ki Suk} and Lee, {Sang Hee}",
year = "2006",
month = "9",
day = "1",
language = "English",
volume = "16",
pages = "1377--1383",
journal = "Journal of Microbiology and Biotechnology",
issn = "1017-7825",
publisher = "Korean Society for Microbiolog and Biotechnology",
number = "9",

}

Jeong, SH, Bae, IK, Sohn, SG, Park, KO, An, YJ, Sung, KH, Jang, SJ, Heo, MJ, Yang, KS & Lee, SH 2006, 'First Detection of blaIMP-1 in clinical isolated multiresistant acinetobacter baumannii from Korea', Journal of microbiology and biotechnology, vol. 16, no. 9, pp. 1377-1383.

First Detection of blaIMP-1 in clinical isolated multiresistant acinetobacter baumannii from Korea. / Jeong, Seok Hoon; Bae, Il Kwon; Sohn, Seung Ghyu; Park, Kwang Ok; An, Young Jun; Sung, Kwang Hoon; Jang, Seon Ju; Heo, Myong Jin; Yang, Ki Suk; Lee, Sang Hee.

In: Journal of microbiology and biotechnology, Vol. 16, No. 9, 01.09.2006, p. 1377-1383.

Research output: Contribution to journalArticle

TY - JOUR

T1 - First Detection of blaIMP-1 in clinical isolated multiresistant acinetobacter baumannii from Korea

AU - Jeong, Seok Hoon

AU - Bae, Il Kwon

AU - Sohn, Seung Ghyu

AU - Park, Kwang Ok

AU - An, Young Jun

AU - Sung, Kwang Hoon

AU - Jang, Seon Ju

AU - Heo, Myong Jin

AU - Yang, Ki Suk

AU - Lee, Sang Hee

PY - 2006/9/1

Y1 - 2006/9/1

N2 - Among 46 Acinetobacter baumannii isolates collected in 2004, two imipenem-resistant isolates were obtained from clinical specimens taken from patients hospitalized in Busan, Republic of Korea. Two carbapenemase-producing isolates were further investigated to determine the mechanism of resistance. These isolates were analyzed by antibiotic susceptibility testing, microbiological tests of carbapenemase activity, determination of pI, transconjugation test, enterobacterial repetitive consensus (ERIC)-PCR, and DNA sequencing. Two cases of infection by A. baumannii producing the IMP-1 β-lactamase were detected. The isolates were characterized by a modified cloverleaf synergy test and EDTA-disk synergy test. Isoelectric focusing of crude bacterial extracts revealed nitrocefin-positive bands with a pI value of 9.0. PCR amplification and characterization of the amplicons by direct sequencing indicated that the isolates carried a blaIMP-1 determinant. The isolates were characterized by a multidrug resistance phenotype, including penicillins, extended-spectrum cephalosporins, carbapenems, and aminoglycosides. These results indicate that the observed imipenem resistance of two Korean A. baumannii isolates was due to the spread of an IMP-1-producing clone. Our microbiological test of carbapenemase activity is simple to screen class B metallo-β-lactamase-producing clinical isolates to determine their clinical impact and to prevent further spread. This study shows that the blaIMP-1 resistance determinant, which is emerging in Korea, may become an emerging therapeutic problem, since clinicians are advised not to use extended-spectrum cephalosporins, imipenem, and aminoglycosides. This observation emphasizes the importance of having effective control measures in Asian hospitals, such as early detection of colonized patients, isolation procedures, and a judicious use of antibiotics.

AB - Among 46 Acinetobacter baumannii isolates collected in 2004, two imipenem-resistant isolates were obtained from clinical specimens taken from patients hospitalized in Busan, Republic of Korea. Two carbapenemase-producing isolates were further investigated to determine the mechanism of resistance. These isolates were analyzed by antibiotic susceptibility testing, microbiological tests of carbapenemase activity, determination of pI, transconjugation test, enterobacterial repetitive consensus (ERIC)-PCR, and DNA sequencing. Two cases of infection by A. baumannii producing the IMP-1 β-lactamase were detected. The isolates were characterized by a modified cloverleaf synergy test and EDTA-disk synergy test. Isoelectric focusing of crude bacterial extracts revealed nitrocefin-positive bands with a pI value of 9.0. PCR amplification and characterization of the amplicons by direct sequencing indicated that the isolates carried a blaIMP-1 determinant. The isolates were characterized by a multidrug resistance phenotype, including penicillins, extended-spectrum cephalosporins, carbapenems, and aminoglycosides. These results indicate that the observed imipenem resistance of two Korean A. baumannii isolates was due to the spread of an IMP-1-producing clone. Our microbiological test of carbapenemase activity is simple to screen class B metallo-β-lactamase-producing clinical isolates to determine their clinical impact and to prevent further spread. This study shows that the blaIMP-1 resistance determinant, which is emerging in Korea, may become an emerging therapeutic problem, since clinicians are advised not to use extended-spectrum cephalosporins, imipenem, and aminoglycosides. This observation emphasizes the importance of having effective control measures in Asian hospitals, such as early detection of colonized patients, isolation procedures, and a judicious use of antibiotics.

UR - http://www.scopus.com/inward/record.url?scp=33750186699&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750186699&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33750186699

VL - 16

SP - 1377

EP - 1383

JO - Journal of Microbiology and Biotechnology

JF - Journal of Microbiology and Biotechnology

SN - 1017-7825

IS - 9

ER -